Ponazuril
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80071759
CAS NO.69004-04-2
Purity 98%
MDL NumberMFCD09263475
Molecular FormulaC18H14F3N3O6S
Molecular Weight 457.384
Melting point: 241~246°C
| Item | Information |
|---|---|
| Mechanism of Action | Ponazuril is a triazine-based antiprotozoal drug and a metabolite of toltrazuril. It acts by inhibiting enzyme systems in protozoa and/or decreasing pyrimidine synthesis, specifically targeting the apicoplast organelle in apicomplexan parasites. |
| Indications | – Approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by Sarcocystis neurona.<br>- Used in small animals (cats, dogs, rabbits) for treating coccidiosis. |
| Dosage Forms | Available as an oral paste (Marquis) for horses. |
| Common Dosage | – For EPM in horses: 5 mg/kg once daily for a minimum of 28 days.<br>- For coccidiosis in small animals: Doses range from 20 to 50 mg/kg for 2 to 5 days. |
| Pharmacokinetics | – Achieves steady-state concentrations in horse cerebrospinal fluid (CSF) after about one week.<br>- Half-life in horses is approximately 1.6 to 4.5 days. |
| Efficacy | – Approximately 60% efficacy in treating EPM in horses.<br>- Effective at blocking merozoite production in vitro at concentrations of 1 µg/mL. |
| Special Notes | – An initial loading dose (e.g., 15 mg/kg) may be used to achieve therapeutic concentrations more quickly in horses.<br>- Treatment duration may be extended beyond 28 days based on clinical response. |
| Trade Names | Marquis (oral paste for horses). |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
